BTSG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BrightSpring Health Services Inc (BTSG) is a good buy for a beginner investor with a long-term investment strategy and $50,000-$100,000 available. The stock has strong growth potential, supported by positive analyst ratings, robust financial performance, and a favorable long-term growth outlook. Despite the lack of immediate trading signals and neutral technical indicators, the company's fundamentals and positive catalysts make it a solid investment opportunity.
The technical indicators are mixed but lean slightly positive. The MACD is below 0 and negatively contracting, suggesting limited momentum. RSI is neutral at 56.474, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support and resistance levels are Pivot: 42.696, R1: 44.866, S1: 40.526, R2: 46.206, S2: 39.186. The stock is trading near the pivot level, indicating potential for upward movement.
Analysts have consistently raised price targets, with the most recent targets ranging from $52 to $60, reflecting strong confidence in the company's growth.
The company projects a 15%-20% adjusted EBITDA CAGR from 2026-2028, supported by historical growth rates of 18%-19%.
Recent sale of ResCare Community Living to Sevita enhances focus on core business segments.
Strong Q4 financial performance with revenue up 29.26% YoY and net income up 381.78% YoY.
Gross margin decreased by 5.76% YoY in Q4 2025, which may indicate rising costs or pricing pressures.
Neutral sentiment from hedge funds and insiders, with no significant trading trends observed.
Stock trend analysis suggests a 50% chance of minor declines in the short term (-1.29% next day, -1.17% next week, -1.09% next month).
In Q4 2025, BrightSpring Health Services demonstrated strong financial growth. Revenue increased by 29.26% YoY to $3.55 billion, net income surged 381.78% YoY to $77.08 million, and EPS rose 325% YoY to $0.34. However, gross margin declined to 11.62%, down 5.76% YoY, which warrants monitoring.
Analysts are highly positive on BTSG, with multiple firms raising price targets recently. UBS, TD Cowen, and Mizuho have all highlighted the company's strong growth trajectory and business diversification. Price targets now range from $48 to $60, with most firms maintaining Buy or Outperform ratings.
